Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings. “Our analysis shows ...

PLA codes like 0249U are essential building blocks for new diagnostics, as they solidify assay recognition within payers’ billing systems and often represent a significant step in test validation.

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., has successfully transferred the Proprietary Laboratory Analyses (PLA) code 0249U from Theralink Technologies, allowing recognition and ...

Ignite Proteomics, a subsidiary of IMAC Holdings (BACK), announced the completed transfer of Proprietary Laboratory Analyses, or PLA, code ...

Ignite Proteomics LLC announced the publication of a pivotal study in the British Journal of Cancer, which emphasizes the importance of measuring activated proteins in the AKT–mTOR signaling ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb.

Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary ...

Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), announces the publication of a significant study in the British Journal of ...